Results 171 to 180 of about 1,583,699 (313)
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou+11 more
wiley +1 more source
Goldener, Grüner und „Anderer“ Weg zu Open Access: Statistiken für Österreich
Archambault et al. veröffentlichten 2014 einen Report, der die Open-Access-(OA)-Raten für Publikationen der Jahre 2008–2013 aus allen Ländern des Europäischen Forschungsraums (ERA) sowie für Brasilien, Kanada, Japan und die USA enthält.
Nora Schmidt
doaj
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa+13 more
wiley +1 more source
Multiplikator*innen für eine offene Wissenschaft
Sabrina Stockhusen, Linda Martin
doaj +1 more source
Open Access To Broadband Networks: A Case Study Of The AOL/Time Warner Merger [PDF]
Daniel L. Rubinfeld, Hal J. Singer
openalex +1 more source
Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu+7 more
wiley +1 more source
Open access atmospheric pressure chemical ionization Mass spectrometry for routine sample analysis
Lester C. E. Taylor+2 more
openalex +1 more source
KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock+10 more
wiley +1 more source